News | March 26, 2022
NATHEALTH 8th annual summit in New Delhi from March 28-29.
More than 120 speakers and 5,000 delegates are expected to attend
More than 120 speakers and 5,000 delegates are expected to attend
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Recommendation is based on pivotal data from the phase III POLARIX study
To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
With the implementation of this project, a total of 1,030 acres of cultivable land can be irrigated per crop cycle
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
